RankAlpha logo
Back to Rankings

AVTX

Avalo TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
If LOTUS shows clearly positive efficacy and tolerability, AVTX could rerate sharply because the company is now essentially a one-lead-asset story with management already framing Phase 3 preparation and runway into 2028 [#10-K-2026-03-23].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -13.0.
What can break
Board refresh disclosed in March 2026 is not framed as a disagreement, but governance changes can still add noise around a binary setup [#8-K-2026-03-27].
Momentum
77
Value
41
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.00 · Bull $24.00 · Bear $8.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $36.11
Why
Momentum77 · Δ7d -13.0
Value41 · Δ7d +0.1
Sentiment61 · Δ7d +6.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
77
34% active weight
Current posture
7d trendSoftening
Δ7d
-13.0
Δ21d
-6.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
61
33% active weight
Current posture
7d trendImproving
Δ7d
+6.7
Δ21d
+29.4
Why this grade

Composite grade B. Momentum 76.9 / Value 41.1 / Sentiment 60.7

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$827.91M
Beta
0.90
Shares Out
18.13M
P/E (TTM) · Derived
-5.8
P/S (TTM)
1514.00
P/FCF (TTM) · Derived
-9.95
Rev YoY
-100.0%
EPS YoY
-531.9%
Gross Margin
+54.7%
Op Margin
-34632.3%
Net Debt
-$134.55M
Current Ratio
14.28
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology